ADVERTISEMENT

404

Not Found

Is this what you were looking for?

tag cancer drug development biotech fda

How Vesselon Can Improve the Entire Class of Radiopharmaceuticals
Clayton Larsen - President & CEO, Vesselon, Inc. | Nov 21, 2023 | 3 min read
Vesselon's microspheres optimize radiopharmaceuticals for targeted treatment, enhancing anti-tumor effects.
Bugs as Drugs to Boost Cancer Therapy
Danielle Gerhard, PhD | Jan 18, 2024 | 7 min read
Bioengineered bacteria sneak past solid tumor defenses to guide CAR T cells’ attacks.
How Vesselon Can Improve the Entire Class of Antibody-Drug Conjugates
Clayton Larsen - President & CEO, Vesselon, Inc. | Oct 30, 2023 | 4 min read
Vesselon’s novel co-formulation of gas lipid microspheres and self-assembling liposomes, targeted and activated by commercial ultrasound, would be an ideal adjunct to any of these ADC drugs.
Lazarus Drugs
Kate Yandell | Feb 1, 2015 | 8 min read
While some drugs sail through development, others suffer setbacks, including FDA rejections, before reaching the market.
 
FDA Gives Nod to Melanoma Drug
Jef Akst | Sep 8, 2014 | 2 min read
The US Food and Drug Administration last week approved the first of a new type of immunotherapy that aims to pit a patient’s own immune system against her cancer.
The Vaginal Microbiome is Finally Getting Recognized
Hannah Thomasy, PhD, Drug Discovery News | Sep 25, 2023 | 10+ min read
Vaginal dysbiosis has long been a taboo subject, but studying and optimizing the vaginal microbiome could be a game changer for women's health.
Biotech's Baddies
Bob Grant | Apr 1, 2009 | 10+ min read
Biotech's Baddies More than 60 individuals have been blackballed by the FDA for criminal acts against the agency. Here are some of the worst offenders. By Bob Grant ©Tim Kiusalaas o matter how bad things seem for the United States Food and Drug Administration these days, 20 years ago they were arguably worse. In the late 1980s, the agency was embroiled in a generic-drug scandal, in which FDA administrators accepted bribes fo
The Breakthrough Prize ?Trophy
2024 Breakthrough Prizes in Life Sciences
Danielle Gerhard, PhD | Sep 14, 2023 | 10 min read
This year’s Breakthrough Prizes honor advances in CAR T cancer therapies, cystic fibrosis, and Parkinson’s disease.
Job Outlook 'Excellent' in Cancer Biotech
Karen Young Kreeger | Feb 20, 2000 | 5 min read
Search the Biotechnology Industry Organization's Web site using the keyword "cancer" and you'll come up with pages of companies with at least one product, department, or research program aimed at oncological therapeutics. The late-1998 approval by the Food and Drug Administration (FDA) of Genentech's Herceptin, a monoclonal antibody used to treat metastatic breast cancer, is one attestation to the upswing for biotech cancer products. Typically investment in biotech--and hence hiring--is cyclica
FDA Actions, Economy Affect Biotech Industry
Peg Brickley | Jul 8, 2001 | 4 min read
Increased scrutiny by federal drug regulators and continued mergers and acquisitions activity could curb expansion in biotechnology and pharmaceutical industries, according to analysts and economists. A capacity constraint caused by a shortage of manufacturing facilities also could chill the overheated biotech market and job growth as companies exhaust their three-year funding cycles in the next few years, cautions Robert Toth, portfolio manager of the medical technology fund of EGM Capital in S

Run a Search

ADVERTISEMENT